Are you over 18 and want to see adult content?
More Annotations
A complete backup of justcarkits.co.uk
Are you over 18 and want to see adult content?
A complete backup of thesweetpotato.ca
Are you over 18 and want to see adult content?
A complete backup of internetbusinessschool.co.uk
Are you over 18 and want to see adult content?
A complete backup of tiradentesconcursos.com.br
Are you over 18 and want to see adult content?
A complete backup of bemsertanejo.net
Are you over 18 and want to see adult content?
A complete backup of danizbetonsazeh.blog.ir
Are you over 18 and want to see adult content?
A complete backup of akustressgiler.blogspot.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of mortgageplanet.net
Are you over 18 and want to see adult content?
A complete backup of visitbristol.co.uk
Are you over 18 and want to see adult content?
A complete backup of isotretinoin-us.org
Are you over 18 and want to see adult content?
A complete backup of animemotivation.com
Are you over 18 and want to see adult content?
A complete backup of cannonbeachcabin.net
Are you over 18 and want to see adult content?
A complete backup of redcottagechronicles.com
Are you over 18 and want to see adult content?
Text
dinner offers.
BIA | CHARITY PARTNERSHIP OF THE YEAR The BioIndustry Association (BIA) is proud to be working with Ovarian Cancer Action as its charity partner for 2021. One woman dies in the UK from ovarian cancer every two hours and although five-year survival rates for ovarian cancer are improving, other cancers, such as breast cancer, had better survival rates two generations ago than ovariancancer does today.
BIA | BIA START-UP FESTIVAL The BIA are delighted to announce a new event for emerging companies, the BIA Start-up Festival, which will take place in virtual format this May. This event will bring together the best of rising talent in the sector for a day of networking, 1-1 meetings, and educational sessions designed to build on your existing knowledge and allow you to BIA | UK-EU TRADE AND COOPERATION AGREEMENT 18 Jan 21. BIA Blog. The UK and EU negotiators reached agreement on the future relationship just days before the end of the Brexit transition period, ending UK’s participation in the EU’s Single Market and Customs Union. The UK-EU Trade and Cooperation Agreement concluded on 24 December 2020, was ratified by the UK Parliament on 30December
BIA | RARE DISEASE INDUSTRY GROUP The BIA Rare Disease Industry Group (RDIG) represents a group of innovative bioscience companies that specialise in treatments for rare and ultra-rare diseases. The RDIG is committed to developing recommendations that can pragmatically inform and improve the challenge of ensuring patient access to treatments for rare and ultra-rare conditions GUIDANCE: FREQUENTLY ASKED QUESTIONS Page 3 of 24 8. Section 15 of the CAP conversion guidance clarifies some of the requirements for the UK MAH following the UK’s exit from the EU.However, the requirements to submit texts orBIA | GLYCOVUE LTD
GlycoVue Ltd. GlycoVue is a spin-off from the University of Cambridge and represents the accumulation of more than 15 years of experimental research in near-continuous glucose monitoring in readily accessible biological fluids. GlycoVue combines glucose-responsive smart polymers with advanced holography and AI-enabled smartphone-based CELL AND GENE THERAPY EXPLAINED A GUIDE TO CELL AND GENE CAR-T cell-based medicines include both a gene therapy element (the new receptor molecule) and a cell therapy element (the cells injected back into the patient). BIA REGIONAL FOCUS: ADVANCED THERAPIES IN THE SOUTH WEST The BIA is delighted to announce a South West regional event, this year taking place in virtual format, which will focus on advanced therapies in the South West of the UK. There have been lots of exciting developments and success stories from the region in recent months, across the full developmental pathway, from developing veryearly stage
BIA | HOMEPAGEMEMBERSEVENTSNEWSPOLICYABOUT USJOIN OR LOGIN BIA biotech manifesto 2019. The United Kingdom (UK) will have a general election on Thursday, 12 December. The UK BioIndustry Association (BIA) has launched a biotech manifesto with its recommendations on how political parties can support the innovative UK life sciences sector. BIA | GARDEN PARTY 2021 #BIAGardenParty. Since we will be able to meet in person again from the summer, we have decided to throw a garden party! This will give the community the chance to finally meet face to face and make up for the missed networking opportunities that our traditional January Galadinner offers.
BIA | CHARITY PARTNERSHIP OF THE YEAR The BioIndustry Association (BIA) is proud to be working with Ovarian Cancer Action as its charity partner for 2021. One woman dies in the UK from ovarian cancer every two hours and although five-year survival rates for ovarian cancer are improving, other cancers, such as breast cancer, had better survival rates two generations ago than ovariancancer does today.
BIA | BIA START-UP FESTIVAL The BIA are delighted to announce a new event for emerging companies, the BIA Start-up Festival, which will take place in virtual format this May. This event will bring together the best of rising talent in the sector for a day of networking, 1-1 meetings, and educational sessions designed to build on your existing knowledge and allow you to BIA | UK-EU TRADE AND COOPERATION AGREEMENT 18 Jan 21. BIA Blog. The UK and EU negotiators reached agreement on the future relationship just days before the end of the Brexit transition period, ending UK’s participation in the EU’s Single Market and Customs Union. The UK-EU Trade and Cooperation Agreement concluded on 24 December 2020, was ratified by the UK Parliament on 30December
BIA | RARE DISEASE INDUSTRY GROUP The BIA Rare Disease Industry Group (RDIG) represents a group of innovative bioscience companies that specialise in treatments for rare and ultra-rare diseases. The RDIG is committed to developing recommendations that can pragmatically inform and improve the challenge of ensuring patient access to treatments for rare and ultra-rare conditions GUIDANCE: FREQUENTLY ASKED QUESTIONS Page 3 of 24 8. Section 15 of the CAP conversion guidance clarifies some of the requirements for the UK MAH following the UK’s exit from the EU.However, the requirements to submit texts orBIA | GLYCOVUE LTD
GlycoVue Ltd. GlycoVue is a spin-off from the University of Cambridge and represents the accumulation of more than 15 years of experimental research in near-continuous glucose monitoring in readily accessible biological fluids. GlycoVue combines glucose-responsive smart polymers with advanced holography and AI-enabled smartphone-based CELL AND GENE THERAPY EXPLAINED A GUIDE TO CELL AND GENE CAR-T cell-based medicines include both a gene therapy element (the new receptor molecule) and a cell therapy element (the cells injected back into the patient). BIA REGIONAL FOCUS: ADVANCED THERAPIES IN THE SOUTH WEST The BIA is delighted to announce a South West regional event, this year taking place in virtual format, which will focus on advanced therapies in the South West of the UK. There have been lots of exciting developments and success stories from the region in recent months, across the full developmental pathway, from developing veryearly stage
BIA | CHARITY PARTNERSHIP OF THE YEAR The BioIndustry Association (BIA) is proud to be working with Ovarian Cancer Action as its charity partner for 2021. One woman dies in the UK from ovarian cancer every two hours and although five-year survival rates for ovarian cancer are improving, other cancers, such as breast cancer, had better survival rates two generations ago than ovariancancer does today.
BIA | EVENTS
Held across the UK and beyond, our accessible events enable you to engage with the best thought-leadership in the sector and connect with peers and inspirational sector leaders. Scroll down for our current listings or contact our events team for more information. To download the latest BIA events brochure for 2020 please click here. BIA | MEMBERSHIP DIRECTORY Membership directory. We represent over 300 companies. Our members include start-up, emerging and more established bioscience companies, pharmaceutical companies, academic, research and philanthropic organisations, and service providers to the biosciences sector. Find our members using company name keywords or locations (click on thetabs above
BIA | MMIP VIRTUAL CONFERENCE We’re delighted to announce the annual MMIP conference, to be held virtually on Wednesday 16 June, 13.00 to 17.00. The pandemic has highlighted the importance of global medicines supply chains, and generated unprecedented discussion around the manufacturing of medicines and vaccines; there has even been public discussion in the media about the challenges of manufacturing scale up and batch BIA | NATIONAL SECURITY AND INVESTMENT REGIME OVERVIEW The National Security and Investment (NSI) regime is the UK Government’s new approach to scrutinising and intervening in business transactions, both foreign and domestic, where necessary to protect national security. It gives the Government the powers to screen investments and carry out national security assessments of certain transactions BIA | LIFE SCIENCES 2030 SKILLS STRATEGY The UK BioIndustry Association (BIA) has welcomed today’s publication of the Life Sciences 2030 Skills Strategy . The report is a key deliverable from the Life Sciences Sector Deal 2 and sets out how the UK Life Sciences sector will attract, retain, train and develop the research, manufacturing and technical skills required by a dynamic and diverse UK sector. BIA | ARECOR APPOINTS DR. LINDSEY FOULKES AS CHIEF Arecor Therapeutics plc (“Arecor”, the “Company” or the “Group”) ARECOR APPOINTS DR. LINDSEY FOULKES AS CHIEF OPERATING OFFICER Cambridge, UK, 10 June 2021: Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces the appointment of Dr. Lindsey Foulkes as the Company’s Chief BIA | WHP COMPLETES THE MANUFACTURE OF THEIR LARGEST Multi-disciplinary engineering company WHP were awarded the contract to design and build a fully modularised containment facility. The project comprised the design and manufacture of 122 cGMP modules, making it one of the largest modular cGMP facilities in Europe. BIA | IKSUDA THERAPEUTICS CLOSES $47 MILLION FINANCING ROUND Newcastle, UK, 7 June 2021: Iksuda Therapeutics (Iksuda), the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, today announced it has completed a US $47 million (circa GB £34 million) financing round, co-led by Mirae Asset Capital and its subsidiaries, Celltrion and Premier Partners, with the Company being advised by Ashfords LLP. BIA | WHP COMPLETES NEW CLEANROOM AND PRODUCTION New state of the art cleanroom and production facilities for a leading UK MHRA approved and NHS Accredited Specials Manufacturing Company will assist them in their goal of becoming a centre of medical cannabis excellence for the UK.Menu
All results
* Members
* Member Benefits
* Developing your company * Advisory Committees * Search sector jobs * Submit member jobs * Membership directory* Events
* Supporters
* Submit your sector event* News
* Press releases
* BIA blog
* Member news
* Submit member news* Document library
* Search all news
* Policy
* Leaving the EU
* Finance, tax and investment * Access to medicines * Skills, people and talent * Pre-clinical and clinical research * Medicines Regulation * IP and tech transfer* Manufacturing
* Strategic technologies* Invest in biotech
* About Us
* What is biotech?
* Meet the team
* Our board
* Charity partnership of the year* BIA Vacancies
*
* JOIN or LOGIN
Back
MEMBER LOGIN
Email address
Password
Forgotten password?
| Register
REMEMBER ME
Discover the benefits of BIA membershipScroll for more
.
06 Nov 20
Press Release
BIA RESPONDS TO UK GOVERNMENT STATEMENT ON IRELAND/NORTHERN IRELAND SPECIALISED COMMITTEE INVESTING IN UK BIOTECH HAS NEVER BEEN MORE ATTRACTIVE THE UK HAS NOW LEFT THE EU. VIEW THE BIA BREXIT PORTAL FOR UPDATES06 Nov 20
Press Release
BIA RESPONDS TO THE PUBLICATION OF THE NICE METHODS REVIEWCONSULTATION PAPER
prev
next
@IANWCAMPBELL @INNOVATEUK Thank you for your leadership of @INNOVATEUK, Ian. You’ve done a great job and our sector… HTTPS://T.CO/MJ7JHLDHPX RT @DRMARTINTURNER: Questions and uncertainty remain for #BIOTECH following the #SPENDINGREVIEW. It appears @INNOVATEUK has only beengiven…
We are looking forward to the Digital Skills workshop at #BIOPROCESSUK next week!💡 This session will present a num… HTTPS://T.CO/PRPIJUYMRE RT @NHSENGLAND: An innovative blood test that may spot more than 50 types of cancer will be piloted by the NHS in a world-leading study,Si…
RT @INSTINCTIF_HLS: Hear from some innovative digital companies at #BIOPROCESSUK and vote for your favourite! Good luck to @REFEYNIT@MICR…
@IANWCAMPBELL @INNOVATEUK Thank you for your leadership of @INNOVATEUK, Ian. You’ve done a great job and our sector… HTTPS://T.CO/MJ7JHLDHPX RT @DRMARTINTURNER: Questions and uncertainty remain for #BIOTECH following the #SPENDINGREVIEW. It appears @INNOVATEUK has only beengiven…
We are looking forward to the Digital Skills workshop at #BIOPROCESSUK next week!💡 This session will present a num… HTTPS://T.CO/PRPIJUYMRE RT @NHSENGLAND: An innovative blood test that may spot more than 50 types of cancer will be piloted by the NHS in a world-leading study,Si…
RT @INSTINCTIF_HLS: Hear from some innovative digital companies at #BIOPROCESSUK and vote for your favourite! Good luck to @REFEYNIT@MICR…
@IANWCAMPBELL @INNOVATEUK Thank you for your leadership of @INNOVATEUK, Ian. You’ve done a great job and our sector… HTTPS://T.CO/MJ7JHLDHPXprev
next
1 of 5
LATEST NEWS FROM BIAView all news
* Press Releases
* Member News
* BIA blog
* Our publications
Press Releases
20 Nov 20
Press Release
BIA LAUNCHES REPORT ON RARE DISEASE MEDICINES APPRAISAL The BioIndustry Association's Rare Disease Industry Group (RDIG) has today launched A Rare Chance for Reform in collaboration with PwC, calling for action to ensure that patients are able to access innovative medicines for rare diseases.19 Nov 20
Press Release
SQUEEZED GOVERNMENT BIOMEDICAL INNOVATION BUDGET PUTS FUTURE MEDICINES AT RISK, FOI REVEALS Insufficient government funding is putting the UK’s pipeline of future biomedical innovations at risk, according to data revealed in a Freedom of Information (FOI) request.13 Nov 20
Press Release
GOVERNMENT CONFIRMS R&D TAX CREDIT CAP EXEMPTION TO PROTECT GENUINEBIOTECH COMPANIES
Draft legislation to implement the SME R&D tax credit PAYE cap published yesterday (12 November) confirms that the Government intends to implement a targeted exemption to protect genuine companies, as proposed by the BIA.06 Nov 20
Press Release
BIA RESPONDS TO UK GOVERNMENT STATEMENT ON IRELAND/NORTHERN IRELAND SPECIALISED COMMITTEE 05 NOVEMBER 2020 Steve Bates OBE, Chief Executive of the BIA said: "The real winners from this announcement are patients in Northern Ireland. This gives patients and companies the certainty we have been asking for ahead of31 December 2020.
See More
Member News
26 Nov 20
Member News
LUNAC THERAPEUTICS APPOINTS CARL STERRITT AS CHIEF EXECUTIVE OFFICER LUNAC Therapeutics Ltd (LUNAC), a UK-based drug discovery company focused on the development of advanced life-saving anticoagulants with minimal risk of bleeding, announces that it has appointed Carl Sterritt as Chief Executive Officer.25 Nov 20
Member News
COVID TESTING PIONEER NAMED AS A BIOBUSINESS MOVER AND SHAKER Dr Sally Price, Head of Cell and Translational Science at Medicines Discovery Catapult (MDC) has been named in BioBeat’20 Movers & Shakers in BioBusiness 2020.24 Nov 20
Member News
SELVITA TO ACQUIRE FIDELTA FROM GALAPAGOS Strengthening Selvita’s position as one of the largest preclinical contract research organizations in Europe - Acquisition substantially expands Selvita’s integrated drug discovery services offering - Transaction will almost double Selvita’s revenues - Enterprise value of € 31.2M to be paid in cash - Fidelta to continue performing drug discovery services for Galapagos for the next five years19 Nov 20
Member News
PHARMACEUTICAL INVESTMENT RECOVERY & REDEPLOYMENT SOLUTIONS Sell or redeploy equipment from multiple sites within your company with EquipNet’s Surplus Asset Management Program.See More
BIA blog
26 Nov 20
BIA Blog
SPENDING REVIEW 2020 OFFERS SOME REASSURANCE TO BIOTECH SECTOR BUT THE BIOMEDICAL CATALYST REMAINS UNSECURED Amid gloomy economic predictions and rising public borrowing fuelled by the pandemic, the Chancellor delivered a one-year government spending settlement with investment in jobs and infrastructure to reassure a nervous nation.23 Nov 20
BIA Blog
CEO UPDATE | MONDAY 23 NOVEMBER The news that we’ve all been waiting for is out today, from the UK-sourced Oxford University and AstraZeneca COVID-19 vaccine. The great news is that the vaccine works in Phase III clinical trials. For an industry audience it is worth digging into the complex dataset.16 Nov 20
BIA Blog
CEO UPDATE | MONDAY 16 NOVEMBER Breaking news today that Moderna has released initial data on their mRNA vaccine’s Phase 3 study, which met statistical criteria with a vaccine efficacy of 94.5%. The phase 3 trial was conducted in the US in partnership with BARDA and Operation Warp Speed and based on these interim safety and efficacy data, Moderna intends to submit an application for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) in the coming weeks. It’s great news and following last week’s announcement by Pfizer/Biontech, shows the importance of smaller biotech companies in our innovation ecosystem.12 Nov 20
BIA Blog
LIFE SCIENCE VC INVESTMENTS PERFORM EQUALLY OR BETTER THAN OTHER SECTORS, NEW DATA SHOWS A report published today by the British Business Bank is the most comprehensive analysis of UK life science venture capital performance to date, and it reveals that life science investments have performed equally or better than those in non-life sciences.See More
Our publications
Please find a selection of featured BIA publications below. To see our full publications library, click here.
27 Jan 20
INFLUENCING AND SHAPING OUR SECTOR | BIA UPDATE: OCTOBER 2019 -JANUARY 2020
This quarterly update gives an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences sector, from October 2019 to January 2020.22 Jan 20
Research Publications GLOBAL AND GROWING - UK BIOTECH FINANCING IN 2019 New figures published today (Wednesday 22 January 2020) by the UK BioIndustry Association (BIA) and Informa Pharma Intelligence reveal that the UK biotech sector raised £1.3 billion in 2019.19 Jan 20
UK LIFE SCIENCES: CATALYSING INVESTMENT AND GROWTH This updated interim report sets out how the UK life sciences sector is driving investment and growth and makes the case for increased cost-effective public investment in the sector.11 Nov 19
Guidance document, Policy Briefing, News Report BIA BIOTECH MANIFESTO 2019 The United Kingdom (UK) will have a general election on Thursday, 12 December. The UK BioIndustry Association (BIA) has launched a biotech manifesto with its recommendations on how political parties can support the innovative UK life sciences sector. LATEST EVENTS AT BIAView all events
01 Dec
Conference
17TH ANNUAL BIOPROCESSUK CONFERENCE 2020Online event
10 Feb
Event
BIA COMMITTEE SUMMIT 2021Online event
15 Mar
Workshop
PULSE
Francis Crick InstituteOUR SUPPORTERS
The BioIndustry Association, 7th Floor, Southside, 105 Victoria Street, London, SW1E 6QT ● Tel: +44 (0)20 7630 2180* Privacy statement
2020 The BioIndustry AssociationWeb design by Pixl8
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0